Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2002

View Archived Issues

AVI-4557 completes two phase I studies in drug metabolism

Phase I clinical testing commences for two Igeneon cancer products

E.U. grant helps consortium develop new drugs to treat S. aureus infections

Coley receives funding to develop CpG oligos for enhancement of vaccines

Epratuzumab safe and effective in non-Hodgkin's lymphoma

Positive interim results for AG-858/Gleevec combination therapy in CML

Helix BioPharma's interferon alfa cream for HPV to enter clinic in 2003

Akt inhibitor from Kinetek induces apoptosis in AML cells

E.U. approval obtained for use of Enbrel in psoriatic arthritis

First MAA filed for Hexvix

Temple University scientists synthesize novel sulfone-based antitumor agents

Karo Bio presents novel antithyroid agents with utility in arrhythmia and thyroid hormone disorders

New inhibitors of JNK3, Src and/or Lck kinases in early development at Vertex

Novel series of dual ACE/NEP inhibitors identified at Novartis

Tachykinin NK1 antagonists prepared and tested at Roche

Origenix describes nucleic acid-based agents for hepatitis B virus

Evaluation of capsule presentation of ramoplanin completed

Moxifloxacin NDA filed for bacterial conjunctivitis and ophthalmia neonatorum

Lexicon Genetics and Genentech form drug discovery alliance

Sunesis delivers lead compound series to J&J in collaboration

Drug pipeline for chronic obstructive pulmonary disease

Promising results for a novel anti-CD20 radioimmunotherapy in non-Hodgkin's lymphoma

Phase III results demonstrate superiority of palonosetron over dolasetron for CINV

RDP-58 cleared for clinical testing in chemotherapy-induced diarrhea

Filing for Estorra scheduled for early next year

Phase II Spheramine study commences in late-stage PD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...